SRR934919
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 14.684625492772668
- age_years
- 75
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.551
- G2M_CHECKPOINT+0.483
- INTERFERON_ALPHA_RESPONSE+0.343
- MITOTIC_SPINDLE+0.326
- MYC_TARGETS_V1+0.286
- NOTCH_SIGNALING+0.264
- INTERFERON_GAMMA_RESPONSE+0.236
- MYC_TARGETS_V2+0.172
- DNA_REPAIR+0.164
- ALLOGRAFT_REJECTION+0.156
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.382
- MYOGENESIS-0.367
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.331
- KRAS_SIGNALING_DN-0.316
- APICAL_SURFACE-0.295
- HYPOXIA-0.274
- HEDGEHOG_SIGNALING-0.207
- PANCREAS_BETA_CELLS-0.204
- TNFA_SIGNALING_VIA_NFKB-0.172
- UV_RESPONSE_UP-0.166
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | d708a0d7-edda-46a8-b717-1b48c073c828 | — | — | 0.843 |
| 2 | SRR934887 | — | — | 0.836 |
| 3 | MDT-AP-3168 | Med | Medulloblastoma | 0.811 |
| 4 | AE270FCD-9297-4185-B6CA-02062352DB66 | — | — | 0.802 |
| 5 | 2c2c7f46-2271-42fb-9857-05de4bc0aee6 | — | — | 0.791 |
| 6 | SRR934909 | — | — | 0.786 |
| 7 | 64F4FE1B-1B96-49CC-B4E9-454D971DB7BC | — | — | 0.773 |
| 8 | SRR934751 | — | — | 0.772 |
| 9 | E35A6AA5-331F-489B-8CE1-9D0BC4CDE119 | — | — | 0.772 |
| 10 | SRR934757 | — | — | 0.770 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.551 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.483 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.343 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.326 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.286 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.264 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.236 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.172 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.164 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.156 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.154 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.138 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.135 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.080 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.066 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.059 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.027 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.019 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.008 | Inavolisib | — uncovered |